Association Between Overall Survival and Adverse Events with Lenvatinib Treatment in Patients with Hepatocellular Carcinoma (REFLECT).

Max W. Sung,Richard S. Finn,Shukui Qin,Kwang-Hyub Han,Kenji Ikeda,Ann-Lii Cheng,Masatoshi Kudo,Ryosuke Tateishi,Masafumi Ikeda,Valery Breder,Kun-Ming Rau,Yuk Ting Ma,Angel Alsina,Baek-Yeol Ryoo,Zhenggang Ren,Kalgi Mody,Corina E. Dutcus,Toshiyuki Tamai,Kenichi Saito,Fabio Piscaglia

DOI: https://doi.org/10.1200/jco.2019.37.4_suppl.317

IF: 45.3

2019-01-01

Journal of Clinical Oncology

Abstract:317 Background: In the phase 3 REFLECT study, lenvatinib (LEN) demonstrated a treatment effect on overall survival (OS) by statistical confirmation of non-inferiority to sorafenib (SOR) in patients (pts) with unresectable hepatocellular carcinoma (uHCC), who had not received prior treatment for advanced disease (Kudo M et al, Lancet 2018). Lenvatinib is approved in several major markets for the first line systemic treatment of uHCC. The most common adverse events (AEs) in pts treated with LEN were hypertension and diarrhea. In addition, LEN showed a different AE profile from that of SOR. Pts who received LEN experienced more instances of hypertension, proteinuria, dysphonia, and hypothyroidism than patients who received SOR. Recently, hypertension in LEN-treated pts with differentiated thyroid cancer was shown to be correlated with improved efficacy. Here we report the post hoc analysis exploring whether AEs associated with LEN were correlated with longer OS in REFLECT. Methods: 478 Pts were randomized to receive LEN (12 mg/d for actual body weight ≥ 60 kg or 8 mg/d for actual body weight < 60 kg). Subgroup analyses were conducted based on whether pts treated with LEN experienced any-grade AEs of interest (AEIs). OS was estimated by the Kaplan-Meier method. Results: The AEIs in pts treated with LEN were hypertension (42%), diarrhea (38%), proteinuria (24%), dysphonia (24%), and hypothyroidism (16%). OS was longer in pts who had several AEs of interest than in those who did not (table). Conclusions: In pts treated with LEN, the occurrence of hypertension, diarrhea, proteinuria, or hypothyroidism was generally associated with longer OS in pts with uHCC in this post hoc exploratory analysis. The potential confounding factors at baseline should be further investigated. Clinical trial information: NCT01761266. [Table: see text]